Pharma News, 2025

Whilst 2025 outlooks include cost impacts from existing tariffs, companies have not adjusted their guidance for future pharma-specific ones.

Cedars-Sinai investigators have discovered a signaling interaction between two proteins in cells that controls fat accumulation in the livers of laboratory mice with alcohol-associated liver disease.

A pan-tropomyosin receptor kinase (TRK) inhibitor, zurletrectinib (ICP-723) is said to have demonstrated better safety and efficacy in a registration trial.

The US Department of Health and Human Services (HHS) has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with pandemic potential, including in...

4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for 4D-150 for diabetic m...

The combination of avutometinib (VS-6766), abemaciclib (Verzenio), and fulvestrant (Faslodex) showed a manageable safety profile and early signs of efficacy in patients with ho...

The FDA has cleared an investigational new drug (IND) application for the TROP-2 targeted antibody drug conjugate (ADC), OBI-902, to conduct a phase 1/2 study in patients with solid tu...

Scientists at the University of East Anglia (UEA) have developed a revolutionary new way of uncovering the 'true age' of your heart using MRI

Australian biopharmaceutical company Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III drug candidate DMX-200.

Silo Pharma's SP-26 Implant Achieves All Endpoints In Preclinical Fibromyalgia Study

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Boehringer Ingelheim, the University of Oxford and Cumulus Neuroscience have launched a study to monitor brain activity in individuals with borderline personality disorder (BPD) using new tech...